Pancreatic Cancer

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial

By MedXY 09/10/2025

The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.

Clinical Updates Wellness & Lifestyle

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

By MedXY 09/08/2025

A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.

Medical News Wellness & Lifestyle

Statins: Beyond Heart Health—A New Weapon Against Cancer Prevention

By MedXY 08/30/2025

Recent research uncovers that long-term statin use may prevent certain inflammation-driven cancers by blocking IL-33, heralding new possibilities in cancer prevention strategies.

Medical News Wellness & Lifestyle

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk

By MedXY 08/05/2025

A large pooled analysis across continents confirms a linear, dose-dependent association between alcohol consumption and pancreatic cancer risk—independent of smoking status and with significant public health implications.

Clinical Updates Wellness & Lifestyle

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.

Wellness & Lifestyle

Alcohol and Pancreatic Cancer: Emerging Evidence of Risk

By MedXY 07/30/2025

New research strengthens the link between alcohol consumption and pancreatic cancer, highlighting both dose-dependent and threshold risks.